FibroGen, Inc. (FGEN)
Total Valuation
FibroGen has a market cap or net worth of $236.06 million. The enterprise value is $204.44 million.
Market Cap | 236.06M |
Enterprise Value | 204.44M |
Important Dates
The next estimated earnings date is Monday, May 6, 2024, after market close.
Earnings Date | May 6, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
FibroGen has 98.77 million shares outstanding. The number of shares has increased by 3.98% in one year.
Shares Outstanding | 98.77M |
Shares Change (YoY) | +3.98% |
Shares Change (QoQ) | +0.27% |
Owned by Insiders (%) | 6.37% |
Owned by Institutions (%) | 71.45% |
Float | 82.99M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | 61.35 |
PS Ratio | 1.60 |
Forward PS | 1.47 |
PB Ratio | n/a |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 1.38 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.52
Current Ratio | 1.52 |
Quick Ratio | 1.14 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -17.30 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -58.70% |
Return on Capital (ROIC) | n/a |
Revenue Per Employee | $304,016 |
Profits Per Employee | -$584,840 |
Employee Count | 486 |
Asset Turnover | 0.31 |
Inventory Turnover | 0.46 |
Taxes
In the past 12 months, FibroGen has paid $3,000 in taxes.
Income Tax | 3,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -87.51% in the last 52 weeks. The beta is 0.66, so FibroGen's price volatility has been lower than the market average.
Beta (1Y) | 0.66 |
52-Week Price Change | -87.51% |
50-Day Moving Average | 1.93 |
200-Day Moving Average | 1.95 |
Relative Strength Index (RSI) | 56.05 |
Average Volume (30 Days) | 2,627,211 |
Short Selling Information
The latest short interest is 5.53 million, so 5.60% of the outstanding shares have been sold short.
Short Interest | 5.53M |
Short Previous Month | 6.52M |
Short % of Shares Out | 5.60% |
Short % of Float | 6.66% |
Short Ratio (days to cover) | 3.12 |
Income Statement
In the last 12 months, FibroGen had revenue of $147.75 million and -$284.23 million in losses. Loss per share was -$2.92.
Revenue | 147.75M |
Gross Profit | 128.90M |
Operating Income | -281.82M |
Pretax Income | -284.23M |
Net Income | -284.23M |
EBITDA | -258.77M |
EBIT | -268.70M |
Loss Per Share | -$2.92 |
Balance Sheet
The company has $235.59 million in cash and $203.96 million in debt, giving a net cash position of $31.63 million or $0.32 per share.
Cash & Cash Equivalents | 235.59M |
Total Debt | 203.96M |
Net Cash | 31.63M |
Net Cash Per Share | $0.32 |
Equity / Book Value | -204.17M |
Book Value Per Share | -2.07 |
Working Capital | 113.89M |
Cash Flow
In the last 12 months, operating cash flow was -$315.02 million and capital expenditures -$2.52 million, giving a free cash flow of -$317.54 million.
Operating Cash Flow | -315.02M |
Capital Expenditures | -2.52M |
Free Cash Flow | -317.54M |
FCF Per Share | -$3.26 |
Margins
Gross margin is 87.24%, with operating and profit margins of -190.74% and -192.37%.
Gross Margin | 87.24% |
Operating Margin | -190.74% |
Pretax Margin | -192.37% |
Profit Margin | -192.37% |
EBITDA Margin | -175.14% |
EBIT Margin | -181.86% |
FCF Margin | -214.91% |
Dividends & Yields
FibroGen does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -3.98% |
Shareholder Yield | -3.98% |
Earnings Yield | -120.41% |
FCF Yield | -134.51% |
Analyst Forecast
The average price target for FibroGen is $5.00, which is 112.77% higher than the current price. The consensus rating is "Sell".
Price Target | $5.00 |
Price Target Difference | 112.77% |
Analyst Consensus | Sell |
Analyst Count | 5 |
Revenue Growth Forecast (5Y) | 11.71% |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
FibroGen has an Altman Z-Score of -7.27 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -7.27 |
Piotroski F-Score | 2 |